Additionally, these results may suggest that in the patients with high tumor burden, Lu177-PSMA therapy may be administrated at tolerably higher activities before side effects in dose-limiting organs such as kidneys and salivary glands become apparent. This evidence concerns the gene FOLH1 and neoplasm.